Is Medicus Pharma Ltd. (MDCX) Stock Gaining Momentum With Innovative Skin Cancer Treatment Technology?

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Medicus Pharma Ltd. (NASDAQ:MDCX) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 15 that MDCX announced the filing of a Rare Pediatric Disease Designation request with the U.S. Food and Drug Administration for SkinJect, its investigational doxorubicin-containing microneedle array patch, for the treatment of basal cell carcinoma in patients with Gorlin Syndrome.

The submission follows the company’s previously filed Orphan Drug Designation application and ongoing FDA review of its registrational study design. MDCX reported that recent Phase 2 results demonstrated encouraging clinical and complete response rates while maintaining a favorable safety profile. If granted, the designation could support the company’s regulatory strategy and potentially provide eligibility for a Rare Pediatric Disease Priority Review Voucher, subject to future FDA approval.

Is Medicus Pharma Ltd. (MDCX) Stock Gaining Momentum With Innovative Skin Cancer Treatment Technology?

Separately, Medicus Pharma Ltd. (NASDAQ:MDCX) announced earlier on June 8 that it had filed a substantial modification application through the European Union CTIS for the planned Phase 2b study of Teverelix in advanced prostate cancer. The study is intended to refine dose selection while further evaluating the therapy’s pharmacokinetics, pharmacodynamics, efficacy, and safety before registrational development. The program is focused on patients with elevated cardiovascular risk who require androgen deprivation therapy and builds on the company’s previous regulatory discussions with the FDA regarding its clinical development strategy for advanced prostate cancer.

Medicus Pharma Ltd. (NASDAQ:MDCX) is a biotechnology company focused on advancing early-stage therapeutic candidates through clinical development and partnering with larger pharmaceutical companies for commercialization.

While we acknowledge the risk and potential of MDCX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MDCX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1